BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221024
DTEND;VALUE=DATE:20221027
DTSTAMP:20260516T035239
CREATED:20220824T114426Z
LAST-MODIFIED:20220824T114426Z
UID:35001-1666569600-1666828799@www.pharmajournalist.com
SUMMARY:4th TIL Therapies Summit
DESCRIPTION:Commercialization looks set to propel TIL therapy into the spotlight for adoptive cell therapy\, and the 4th TIL Therapies Summit arrives to finally reunite the community in-person this October in Boston\, MA. \nFrom preclinical conversations to the latest developments in streamlined manufacturing this year’s meeting will be the most comprehensive guide for addressing the unique challenges of TIL development to bolster and strengthen your pipelines to achieve your 2022/23 milestones. \nWith 20+ world-class speakers and over 100 senior attendees from around the globe\, join the largest community of TIL-targeted drug development experts for a deep dive into clinical development progress\, lessons learnt and novel strategies to maximize TIL-targeting to recognize and capitalize on this outstanding approach in adoptive cell therapy! \nHere’s your exclusive snapshot of the world class speaker faculty: \n\nMichael Lotze\, Chief Cellular Therapy Officer\, Nurix Therapeutics\nMark Dudley\, Chief Scientific Officer\, InsTIL Bio\nDaniel J Powell Jr\, Associate Professor of Pathology and Laboratory Medicine\, University of Pennsylvania\nParameswaran Hari\, SVP Clinical Sciences\, Iovance Biotherapeutics\nNick Restifo\, Stealth Explorer\, Immunotherapy\nKarrie Wong\, Director Cell Therapy\, KSQ Therapeutics\nAndrew Weinberg\, Chief Scientific Officer\, AgonOx\nJan Ter Meulen\, Chief Scientific Officer\, Obsidian Therapeutics\nTom Henley\, Chief Scientific Officer\, Intima Biosciences\nStephanie Woodall\, Director – Head of Quality\, KSQ Therapeutics\nSylvia Lee\, Associate Professor\, Program in Immunology Clinical Research Division\, Fred Hutchinson Cancer Research Center\nUlrik Cordes\, Founder & Chief Executive Officer\, Cbio\n\nLearn from pioneering trailblazers in TIL development from the National Cancer Institute & University of Pennsylvania alongside leading industry representatives from the likes of Iovance\, Instil Bio and Obsidian Therapeutics. \nAs a host of developers look to bridge to the next generation of TIL therapies\, now is the time to leverage actionable insights to ensure you are set to capitalize on this achieve significant expansion in your development. \nJoin senior leaders from leading biotech\, clinical and academic institutes to discuss data-driven and solution-based approaches to supercharge your TIL therapy towards commercialization. \nTo know more visit: https://ter.li/ygtovu
URL:https://www.pharmajournalist.com/event/4th-til-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:https://ter.li/ygtovu
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221025
DTEND;VALUE=DATE:20221028
DTSTAMP:20260516T035239
CREATED:20220708T072935Z
LAST-MODIFIED:20220708T072935Z
UID:34589-1666656000-1666915199@www.pharmajournalist.com
SUMMARY:6th Annual Gene Therapy for Rare Disorders Europe Summit 2022
DESCRIPTION:As more and more companies gear up for clinical activity and near approval decisions\, the need to have an in-depth understanding of the regulatory frameworks and how these feed into clinical development and manufacturing processes is as vital as ever. \nThis year’s summit is dedicated to gaining European regulatory clarity to progress efficient and robust gene therapies for rare diseases. By giving voice to pioneering drug developers with success stories to share\, experts in regulatory affairs\, and the regulators themselves\, this meeting is your comprehensive guide to unpicking the thorniest regulatory challenges. \nAcross three carefully curated days\, this streamlined one-track summit will unite key gene therapy leaders from large pharma to ground-breaking biotech\, academics to exciting service providers\, all with the purpose of paving a way forward to successfully launch gene therapy products in Europe. \nTo know more visit: https://bit.ly/3ysiVts
URL:https://www.pharmajournalist.com/event/6th-annual-gene-therapy-for-rare-disorders-europe-summit-2022/
LOCATION:London Marriott Hotel Regents Park\, 128 King Henry’s Road\, London\, NW3 3ST\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221025
DTEND;VALUE=DATE:20221028
DTSTAMP:20260516T035239
CREATED:20220801T092348Z
LAST-MODIFIED:20220801T092348Z
UID:34838-1666656000-1666915199@www.pharmajournalist.com
SUMMARY:7th Annual Computational Drug Development (CDD) for Biologics Summit
DESCRIPTION:Returning to Boston this October\, the 7th Annual Computational Drug Development (CDD) for Biologics Summit will continue to build on the reputation of past meetings while diving into the latest innovations in the industry. This year’s summit will highlight methods and best-practices to extrapolating data & leveraging deep learning for novel\, complex biologics pipeline progression.  \nAcross 3 days\, we will unite leading experts including AbbVie\, GSK\, Amgen\, Genentech\, Takeda & many more to: \n\nOvercome data availability and collection challenges to support machine learning and in silico drug discovery and development for biologics\nRefine high throughput screening methods for novel antibody candidates to shorten your drug development cycles\nAdvance the next generation of computational biology in designing complex antibodies – including multifunctional\, multi-specific antibodies\nEmpower the predictability of protein structures and protein-protein interactions for better drug development\nOptimize your development cycle and decision making using computational data\n\nFind out more – https://ter.li/ec2qbx
URL:https://www.pharmajournalist.com/event/7th-annual-computational-drug-development-cdd-for-biologics-summit/
LOCATION:Boston Marriott Burlington\, One Burlington Mall Road\, Burlington\, MA\, 01803\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221026
DTEND;VALUE=DATE:20221028
DTSTAMP:20260516T035239
CREATED:20220812T122604Z
LAST-MODIFIED:20220812T122604Z
UID:34912-1666742400-1666915199@www.pharmajournalist.com
SUMMARY:Protein Engineering Biocatalysis Congress
DESCRIPTION:The Protein Engineering Biocatalysis Congress is the unique meeting point of industry\, academia and service providers which will enable protein engineering and biocatalysis enthusiasts to industrialize sustainable enzyme products and increase product efficiency globally. \nThis event will highlight case studies on scaling up protein engineering technologies for commercial scale. It is your opportunity to analyze developments in protein engineering for biocatalysis to establish sustainable\, scalable and cost-efficient API manufacturing. \nTo know more visit: www.proteinengineeringglobal.com
URL:https://www.pharmajournalist.com/event/protein-engineering-biocatalysis-congress/
LOCATION:Philadelphia\, USA (venue TBC)
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR